Brief: Genelux Publishes Positive Topline Data From Phase 2 Viro-15 Trial Of Olvi-Vec In Platinum-Resistant Or Refractory Ovarian Cancer
25/05/2023 22:53
May 25 (Reuters) - Genelux Corp GNLX.O :
* GENELUX CORPORATION ANNOUNCES PUBLICATION OF POSITIVE
TOPLINE
DATA FROM PHASE 2 VIRO-15 TRIAL EVALUATING OLVIMULOGENE
NANIVACIREPVEC (OLVI-VEC) IN PLATINUM-RESISTANT OR REFRACTORY
OVARIAN CANCER IN THE JOURNAL OF THE AMERICAN MEDICAL
ASSOCIATION (JAMA) ONCOLOGY
* GENELUX CORP - PHASE 2 TRIAL OF OLVI-VEC-PRIMED
IMMUNOCHEMOTHERAPY IN HEAVILY PRE-TREATED PATIENTS MET PRIMARY
ENDPOINT
* GENELUX CORP - STUDY GENERATED PROMISING PROGRESSION-FREE
SURVIVAL & DEMONSTRATED CLINICAL REVERSAL OF PLATINUM RESISTANCE
AND REFRACTORINESS
Source text for Eikon: ID:nGNX5P3Krj
Further company coverage: GNLX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Genelux
See all newsGenelux posts wider-than-expected Q2 loss on higher R&D expenses
Genelux Corp expected to post a loss of 20 cents a share - Earnings Preview
Genelux Q1 net loss widens, misses analyst expectations
Brief: Genelux Corporation Announces Pricing Of $20.0 Million Underwritten Public Offering Of Common Stock
Brief: Genelux Corporation Announces Proposed Public Offering of Common Stock